Novel therapies for chronic lymphocytic leukemia.

@article{Mavromatis2004NovelTF,
  title={Novel therapies for chronic lymphocytic leukemia.},
  author={Blanche H Mavromatis and Bruce D Cheson},
  journal={Blood reviews},
  year={2004},
  volume={18 2},
  pages={137-48}
}
New therapies for chronic lymphocytic leukemia (CLL) are moving away from non-specific cytotoxic to more targeted approaches. The monoclonal antibody alemtuzumab induces responses in 33% to 43% of patients with relapsed or refractory disease, with 2-5% CR. Side effects include infusional reactions as well as immunosuppressive effects. Rituximab has limited activity in relapsed refractory patients, but response rates are comparable to follicular non-Hodgkin's lymphoma in untreated patients… CONTINUE READING
15 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Similar Papers

Loading similar papers…